Alzforum (Alzheimer Research Forum), 2016-12: Report of the December 2016 CTAD session at which the second phase 3 trial in mild Alzheimer's disease (n=800) was presented as negative and the sponsor's monotherapy cohort analysis was rejected by attending clinicians and statisticians.
The reported subgroup analyses are, in fact, uninformative, because they lacked an appropriate placebo group
Alzforum (Alzheimer Research Forum), 2016-12: Report of the December 2016 CTAD session at which the second phase 3 trial in mild Alzheimer's disease (n=800) was presented as negative and the sponsor's monotherapy cohort analysis was rejected by attending clinicians and statisticians. Page undated; dated to CTAD 8-10 December 2016, San Diego, which it reports. Quotes Paul Aisen (Alzheimer's Therapeutic Research Institute) and Suzanne Hendrix (Pentara) on the non-randomised comparisons; the piece also records that the statistical analysis plan was changed before database lock and that 'both studies are entirely negative'. Journalism, not peer review, but it names the on-record critics. LINK CHECK: alzforum.org returns HTTP 403 to automated clients from this host; the text was read and the excerpt verified against the Internet Archive capture in archive_url, which loads. Study type: news.
